Humana (HUM) Q3 2026 Earnings Call Transcript

Humana raised its full-year 2026 adjusted EPS floor to $9.50 from $9.00, citing results ahead of plan, while Q3 adjusted results swung to a $0.70-per-share loss from $3.24 profit a year earlier, primarily due to Star-rating headwinds. Management reported a 4.17 member-weighted Star rating for bonus year 2028 and expects 2027 Medicare Advantage membership to grow, while targeting margin recovery toward 3% by 2028. The BlackRock joint venture is expected to reduce the GAAP debt-to-cap ratio by about 130 basis points in Q4; management also expects roughly $900 million in pretax proceeds from the Gentiva minority-interest sale.

Analysis

The more investable signal is a shift from repairing Medicare Advantage economics through enrollment growth to pricing for margin and controlling costs. That can improve unit economics even if 2027 membership growth disappoints—but it also makes AEP retention and mix the key near-term test. Early sales are not enough: lost members can leave fixed costs less well absorbed, while aggressive benefit reductions could weaken retention or invite competitors to target Humana’s customers.

For the next 1–3 months, AEP enrollment and the December 10 investor update matter more than the raised 2026 outlook. Management’s 8%–9% core medical trend and 14%–15% Part D trend assumptions create execution risk: pricing may cover expected costs, but drug utilization and the health-technology pipeline could outrun bids. The Florida CenterWell pressure appears geographically contained by management’s account; verify subsequent segment results before treating it as resolved.

The 2028 Star-rating upside is real optionality, not recurring earnings to capitalize at face value. Competitors can improve ratings, membership mix can change, and some benefit flows to providers; management has not quantified the net benefit. The BlackRock transaction improves reported capital flexibility and removes a prospective funding pressure, but does not by itself prove better clinic-level returns; future clinic purchase rights preserve capital demands. BlackRock’s disclosed role is not enough to support a standalone BLK trade. Over 6–18 months, Humana’s margin recovery is credible but remains conditional on pricing, medical-cost control, and retention.

Key Decisions for Investors

• Keep HUM on a positive watchlist rather than chase the guidance raise. Reassess after AEP data and the December 10 update; prioritize retention and 2027 margin assumptions over early new-sales commentary.
• Consider a staged HUM long only if AEP results support membership stability and management confirms a path to margin improvement without raising cost-trend assumptions. No price target is warranted from the supplied information.
• Falsify the recovery thesis if enrollment or retention materially disappoints, medical or Part D costs exceed bid assumptions, or management walks back 2027 margin progress. Track the individual MA margin trajectory and CenterWell results for evidence.
• Treat the 2028 Star benefit and lower debt-to-cap ratio as upside and balance-sheet flexibility, respectively—not as proof of durable recurring EPS growth. Verify transaction accounting, clinic economics, and the eventual Star-related earnings bridge.